1. Home
  2. NXP vs RLMD Comparison

NXP vs RLMD Comparison

Compare NXP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Select Tax Free Income Portfolio

NXP

Nuveen Select Tax Free Income Portfolio

HOLD

Current Price

$14.40

Market Cap

744.2M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.35

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXP
RLMD
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
744.2M
661.9M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
NXP
RLMD
Price
$14.40
$6.35
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
137.7K
2.3M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$13.73
$0.55
52 Week High
$14.65
$8.00

Technical Indicators

Market Signals
Indicator
NXP
RLMD
Relative Strength Index (RSI) 58.76 42.80
Support Level $14.35 $6.17
Resistance Level $14.49 $7.34
Average True Range (ATR) 0.10 0.45
MACD 0.01 0.01
Stochastic Oscillator 71.70 1.75

Price Performance

Historical Comparison
NXP
RLMD

About NXP Nuveen Select Tax Free Income Portfolio

Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: